Benign Prostatic Hyperplasia Treatment Market Size to Gain USD 12.9 BN by 2030

According to Nova one advisor, the global Benign Prostatic Hyperplasia Treatment market was valued at USD 6.48 billion in 2021 and it is expected to hit around USD 12.9 billion by 2030 with a CAGR of 5.68% during the forecast period 2022 to 2030.

Get the Free Sample Copy of Report@

The prostate is a walnut-sized gland situated just below the bladder in front of the rectum and adjacent to the urethra as part of the male reproductive system. The prostate gland, which consists of four lobes (anterior, posterior, lateral, and medial), generates a fluid that combines with seminal vesicle secretions to generate most of the seminal fluid volume.

Benign prostatic hyperplasia (BPH) is a progressive disorder, wherein the prostate expands as part of the aging process or as a result of a disease. Incidence of benign prostatic hyperplasia increases significantly with age. Prostate development between puberty and the middle age is generally negligible. The exact cause of BPH is unknown, but the disease most frequently occurs in elderly males. It is probably caused due to hormonal changes. Several theories suggest that greater estrogen or dihydrotestosterone concentrations lead to hyperplastic development, although none are conclusive. The function of testosterone in BPH growth is still uncertain.

Currently, benign prostatic hyperplasia is one of the most common benign tumors observed in men across the globe. Benign prostatic hyperplasia is more prevalent in men aged 40 years and above. A study by the National Center for Biotechnology Information (NCBI) stated that the risk of benign prostatic hyperplasia is less common among the population of Asia than in the Caucasian population in the West. Around 50% of men below the age of 60 who underwent surgery for benign prostatic hyperplasia had a heritable form of the disease.

With progressively aging population and changing population profile in nearly all societies, benign prostatic hyperplasia is expected to become a major challenge for all health care systems. It is anticipated to become even more prevalent in men during the forecast period.

Immediate Delivery Available | Buy this Premium Research Report@

Report Scope of the Benign Prostatic Hyperplasia Treatment Market

Report Coverage


Market Size

USD 12.9 Billion by 2030

Growth Rate

CAGR of 5.68% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year


Forecast Period

2022 to 2030

Segments Covered

Treatment, End-user, and Region,


Ask here for more customization study@


 Increase in Geriatric Population to Drive Demand for Benign Prostatic Hyperplasia Treatment

As per the benign prostatic hyperplasia treatment market analysis, increase in geriatric population is a major driver of the global market. Elderly individuals increase the patient pool in major regions of the world. According to the World Health Organization (WHO), the global geriatric population is likely to reach 2 billion (22% of the global population) by 2050 as against 962 million in 2017. The global geriatric population is expected to increase at the fastest rate in developed countries such as the U.S., the U.K., and Japan. Brazil, China, Thailand, and South Korea are likely to have a large geriatric population in the shortest span of time in the near future.

Surge in geriatric population is projected to propel the global benign prostatic hyperplasia treatment market size, as the population is more prone to various age-related as well as chronic diseases. The need for benign prostatic hyperplasia treatment among such patients is relatively higher. This is anticipated to drive the global benign prostatic hyperplasia treatment market.

Rise in Adoption of Minimally Invasive Surgeries to Propel Benign Global Prostatic Hyperplasia Treatment Market

Established types of minimally invasive surgery include electrocautery-based TURP, transurethral incision of the prostate (TUIP), and transurethral vaporization of the prostate (TUVP), although the latter technique is used infrequently. TURP is the most popular minimally invasive surgical procedure for relieving severe medical BPH symptoms, while radical prostatectomy based on open surgery is rarely used in the therapy of BPH, almost solely for indications of prostate cancer.

Adoption of minimally invasive surgeries has been increasing significantly due to various advantages such as less post-operative pain, less blood loss, reduced hospital stay, and faster recovery. This is likely to propel the global benign prostatic hyperplasia (BPH) treatment market during the forecast period.

Growth in Geriatric Population to Augment Global Benign Prostatic Hyperplasia Treatment Market

Prostate development is generally negligible between puberty and middle age; however, hormonal modifications could cause the gland to enlarge when a person reaches age 40 (for most males). Studies of autopsy have found the histological incidence of BPH. Thus, increase in geriatric population that is prone to urological diseases is projected to drive the benign prostatic hyperplasia (BPH) treatment market in the U.S.

Proven High Efficacy to Drive Alpha-blockers Segment

Alpha-blockers block0020alpha-adrenoceptors on the smooth muscle of the prostate, prostatic urethra, and bladder neck, leading to decreased muscle tone and reduction in the bladder obstruction. Alpha-blockers include alfuzosin hydrochloride (Uroxatral), silodosin (Rapaflo), tamsulosin hydrochloride (Flomax), and terazosin (Hytrin). Alpha-blockers are prescribed for men who have moderate to severe BPH symptoms. The proven high efficacy of alpha-blockers is expected to propel the alpha-blockers segment during the forecast period.

Most Preferred Approach for Benign Prostatic Hyperplasia Treatment Propelling TURP Segment

Currently, transurethral resection of the prostate (TURP) is the most preferred approach used by surgeons or urologists for benign prostatic hyperplasia treatment. TURP is an endoscopic electrosurgical procedure involving the removal of a portion of the prostate to relieve voiding obstruction associated with BPH. A specialized cystoscope known as a resectoscope is inserted into the urethra and threaded into the bladder. Following the procedure, most patients stay in the hospital between one and four days for observation. However, the trend is to perform TURP on an outpatient basis, and select patients are discharged within 24 hours of admission.

Regional Outlook of Benign Prostatic Hyperplasia Treatment Market

North America was the leading market for benign prostatic hyperplasia treatment in 2021. Aging population, increase in incidence of benign prostatic hyperplasia, and highly structured health care industry are augmenting the market in the region. Current disease trends indicate that the number of men with benign prostatic hyperplasia and lower urinary tract conditions will increase at a rapid pace in the U.S. in the near future. Rapidly aging population of the U.S. coupled with rise in diabetes and obesity is likely to drive the prevalence of benign prostatic hyperplasia and lower urinary tract conditions. Thus, demand for prostate hypertrophy treatment is estimated to increase in the U.S. in the near future.

Some of the prominent players in the Benign Prostatic Hyperplasia Treatment Market include:

  • Boston Scientific Corporation
  • Teleflex Incorporated
  • Endo International plc
  • Urologix, LLC
  • LISA Laser
  • Olympus Corporation

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Benign Prostatic Hyperplasia Treatment market

  • Treatment
    • Drug Class
      • Alpha-blockers
      • 5-Alpha-reductase Inhibitor (5-ARIs)
      • Phosphodiesterase-5 Enzyme Inhibitor
      • Others
    • Minimally Invasive Surgeries
      • Transurethral Resection of the Prostate (TURP)
      • Transurethral Incision of the Prostate (TUIP)
      • Robotic Surgeries
      • Transurethral Microwave Thermotherapy (TUMT)
      • Prostatic Urethral Lift
      • Others
    • Laser Therapy
    • Others
  • End-user
    • Hospitals
    • Ambulatory Surgical Centers
    • Specialty Clinics
    • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Full Report is Ready | For Purchase Inquiry@

You can place an order or ask any questions, please feel free to| +1 9197 992 333



Back to news